Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- Serum free light chains are an exclusion signal in ATTR-CM, not a confirmation tool.
- A normal screen supports an ATTR pathway but doesn’t prove transthyretin disease; an abnormal result keeps AL amyloidosis in play.
- Free light chains pair with immunofixation. The ratio adds sensitivity; immunofixation adds specificity.
- Renal dysfunction and incidental monoclonal gammopathy can blur interpretation, so results are read in context.
Role of Serum Free Light Chains in the Diagnostic Workup
In ATTR-CM, serum free light chain testing is most useful for facilitating the differential diagnosis. It’s used to help identify a monoclonal pattern that would keep AL amyloidosis or mixed disease in active consideration rather than allowing a premature diagnosis of ATTR-CM. It’s one component of the diagnostic workup and doesn’t confirm transthyretin-mediated disease.
Both Normal and Abnormal Results Require Appropriate Clinical Interpretation
Because the assay screens for a monoclonal process, both normal and abnormal results have important limitations in interpretation. A non-suggestive pattern can support continued evaluation along an ATTR-CM pathway, but it doesn’t confirm transthyretin disease. An abnormal result, on the other hand, should prompt further hematologic evaluation rather than be treated as automatic proof against ATTR-CM because a monoclonal protein and ATTR amyloid can coexist in older patients. This reflects the same diagnostic approach at the center of the differential.
How Free Light Chains Work with Immunofixation
Serum free light chains are read together with serum and urine immunofixation electrophoresis because the two tests provide complementary information: the free light chain ratio adds quantitative sensitivity to an abnormal clonal balance while immunofixation adds specificity by identifying a discrete monoclonal band. Used together, they improve the reliability of a negative monoclonal screen and provide clearer direction when results are abnormal.
Factors Affecting Interpretation
The main limitation is context. Older, multimorbid populations often bring renal dysfunction, incidental monoclonal gammopathy, and other confounders that make mild abnormalities hard to read in isolation, which is why the assay should be interpreted together with immunofixation, the biomarker picture, and the overall phenotype rather than as a stand-alone diagnostic test.
Clinical Decision Point
Serum free light chain results should be interpreted as an exclusion signal, not a diagnosis. A normal screen supports an ATTR-directed pathway only alongside a compatible phenotype and concordant bone-avid imaging; an abnormal ratio maintains suspicion for AL amyloidosis and should prompt immunofixation, hematology input, and consideration of tissue typing before an ATTR-only conclusion.
Frequently Asked Questions
What do serum free light chains screen for in ATTR-CM?
A monoclonal light-chain process that would keep AL amyloidosis in the differential. The test helps ensure AL amyloidosis isn’t overlooked before proceeding with an ATTR-directed diagnostic pathway, rather than confirming transthyretin disease.
Does a normal free light chain result confirm ATTR-CM?
No. It supports continued evaluation along an ATTR pathway, but confirmation still requires a compatible phenotype and concordant bone-avid imaging with monoclonal disease excluded.
Does an abnormal result rule out ATTR-CM?
No. A monoclonal protein and ATTR amyloid can coexist, so an abnormal result should widen hematologic evaluation rather than automatically exclude ATTR-CM.
Why are free light chains read with immunofixation?
Serum free light chain testing provides a sensitive quantitative assessment of free light chain abnormalities, and immunofixation electrophoresis confirms and characterizes the monoclonal protein. Together, these complementary tests improve the detection of an underlying monoclonal gammopathy.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis. Circulation: Heart Failure
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.